Vitamin E, vitamin C, or losartan is not nephroprotectant against cisplatin-induced nephrotoxicity in presence of estrogen in ovariectomized rat model

International Journal of Nephrology

Volumn 2012, Issue , 2012, Pages

  Nematbakhsh, Mehdi ^a,b   Pezeshki, Zahra ^a   Eshraghi Jazi, Fatemeh ^a   Ashrafi, Farzaneh ^a   Nasri, Hamid ^a,b   Talebi, Ardeshir ^a   Safari, Tahereh ^a   Haghighi, Maryam ^a   Mansouri, Azam ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867965433     PISSN: 2090214X     EISSN: 20902158     Source Type: Journal    
DOI: 10.1155/2012/284896     Document Type: Article

References (79)

1. Winston J. A., Safirstein R., Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. The American Journal of Physiology 1985 249 4 F490 F496 2-s2.0-0022134205 (Pubitemid 16185880)
2. Ramesh G., Brian Reeves W., TNF- α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. Journal of Clinical Investigation 2002 110 6 835 842 2-s2.0-0036738517 10.1172/JCI200215606
3. Davis C. A., Nick H. S., Agarwal A., Manganese superoxide dismutase attenuates cisplatin-induced renal injury: importance of superoxide. Journal of the American Society of Nephrology 2001 12 12 2683 2690 2-s2.0-0035195536 (Pubitemid 33115415)
4. Luke D. R., Vadiei K., Lopez-Berestein G., Role of vascular congestion in cisplatin-induced acute renal failure in the rat. Nephrology Dialysis Transplantation 1992 7 1 1 7 2-s2.0-0026530540
5. Deegan P. M., Nolan C., Ryan M. P., Basinger M. A., Jones M. M., Hande K. R., The role of the renin-angiotensin system in cisplatin nephrotoxicity. Renal Failure 1995 17 6 665 674 2-s2.0-0028892278
6. Saleh S., Ain-Shoka A. A., El-Demerdash E., Khalef M. M., Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury. Chemotherapy 2009 55 6 399 406 2-s2.0-70849099078 10.1159/000262453
7. Naqshbandi A., Khan M. W., Rizwan S., Rehman S. U., Khan F., Studies on the protective effect of dietary fish oil on cisplatin induced nephrotoxicity in rats. Food and Chemical Toxicology 2012 50 2 265 273 2-s2.0-84855248444 10.1016/j.fct.2011.10.039
8. Ashrafi F., Nematbakhsh M., Safari T., Talebi A., Nasri H., Khazaei M., Baradaran-Mahdavi M. M., Jafapisheh A., Olia B., Pirhaji O., Hashemi-Nia S. J., Eshraghi F., Pezeshki F., Mortazavi M., A combination of vitamin C and losartan for cisplatin-induced nephrotoxicity in rats. Iranian Journal of Kidney Diseases 2012 6 5 361 365
9. Pérez-Rojas J. M., Guerrero-Beltrán C. E., Cruz C., Sánchez-González D. J., Martínez-Martínez C. M., Pedraza-Chaverri J., Preventive effect of tert-butylhydroquinone on cisplatin-induced nephrotoxicity in rats. Food and Chemical Toxicology 2011 49 10 2631 2637 2-s2.0-79961102014 10.1016/j.fct.2011.07.008
10. Sanchez-Gonzalez P. D., Lopez-Hernandez F. J., Perez-Barriocanal F., Morales A. I., Lopez-Novoa J. M., Quercetin reduces cisplatin nephrotoxicity in rats without compromising its anti-tumour activity. Nephrology Dialysis Transplantation 2011 26 11 3484 3495 2-s2.0-80054900854 10.1093/ndt/gfr195
11. Atasayar S., Gürer-Orhan H., Orhan H., Gürel B., Girgin G., Ozgunes H., Preventive effect of aminoguanidine compared to vitamin E and C on cisplatin-induced nephrotoxicity in rats. Experimental and Toxicologic Pathology 2009 61 1 23 32 2-s2.0-58949089601 10.1016/j.etp.2008.04.016
12. El-Sayed E. S. M., Abd-Ellah M. F., Attia S. M., Protective effect of captopril against cisplatin-induced nephrotoxicity in rats. Pakistan Journal of Pharmaceutical Sciences 2008 21 3 255 261 2-s2.0-55249094911
13. Liu X. H., Li J., Li Q. X., Ai Y. X., Zhang L., Protective effects of ligustrazine on cisplatin-induced oxidative stress, apoptosis and nephrotoxicity in rats. Environmental Toxicology and Pharmacology 2008 26 1 49 55 2-s2.0-42049093792 10.1016/j.etap.2008.01.006
14. Kim Y. H., Kim Y. W., Oh Y. J., Back N. I., Chung S. A., Chung H. G., Jeong T. S., Choi M. S., Lee K. T., Protective effect of the ethanol extract of the roots of Brassica rapa on cisplatin-induced nephrotoxicity in LLC-PK1 cells and rats. Biological and Pharmaceutical Bulletin 2006 29 12 2436 2441 2-s2.0-33845371073 10.1248/bpb.29.2436 (Pubitemid 44885865)
15. Mohan I. K., Khan M., Shobha J. C., Naidu M. U. R., Prayag A., Kuppusamy P., Kutala V. K., Protection against cisplatin-induced nephrotoxicity by Spirulina in rats. Cancer Chemotherapy and Pharmacology 2006 58 6 802 808 2-s2.0-33748443768 10.1007/s00280-006-0231-8 (Pubitemid 44351261)
16. Shimeda Y., Hirotani Y., Akimoto Y., Shindou K., Ijiri Y., Nishihori T., Tanaka K., Protective effects of capsaicin against cisplatin-induced nephrotoxicity in rats. Biological and Pharmaceutical Bulletin 2005 28 9 1635 1638 2-s2.0-24944558836 10.1248/bpb.28.1635 (Pubitemid 41324123)
17. Karimi G., Ramezani M., Tahoonian Z., Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evidence-based Complementary and Alternative Medicine 2005 2 3 383 386 2-s2.0-24344479620 10.1093/ecam/neh103 (Pubitemid 41253351)
18. Shirwaikar A., Malini S., Kumari S. C., Protective effect of Pongamia pinnata flowers against cisplatin and gentamicin induced nephrotoxicity in rats. Indian Journal of Experimental Biology 2003 41 1 58 62 2-s2.0-0347927581 (Pubitemid 36052889)
19. Mansour M. A., Mostafa A. M., Nagi M. N., Khattab M. M., Al-Shabanah O. A., Protective effect of aminoguanidine against nephrotoxicity induced by cisplatin in normal rats. Comparative Biochemistry and Physiology C 2002 132 2 123 128 2-s2.0-0035996321 10.1016/S1532-0456(02)00062-5 (Pubitemid 34777692)
20. Saad S. Y., Al-Rikabi A. C., Protection effects of taurine supplementation against cisplatin-induced nephrotoxicity in rats. Chemotherapy 2002 48 1 42 48 2-s2.0-0036126595 10.1159/000048587 (Pubitemid 34233885)
21. Somani S. M., Husain K., Whitworth C., Trammell G. L., Malafa M., Rybak L. P., Dose-dependent protection by lipoic acid against cisplatin-induced nephrotoxicity in rats: antioxidant defense system. Pharmacology and Toxicology 2000 86 5 234 241 2-s2.0-0034112713 (Pubitemid 30333651)
22. Greggi Antunes L. M., D'arc J., Bianchi M. D. L. P., Protective effects of vitamin C against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dose-dependent study. Pharmacological Research 2000 41 4 405 411 2-s2.0-0033848950 10.1006/phrs.1999.0600
23. Appenroth D., Fröb S., Kersten L., Splinter F. K., Winnefeld K., Protective effects of vitamin E and C on cisplatin nephrotoxicity in developing rats. Archives of Toxicology 1997 71 11 677 683 2-s2.0-0030870380 10.1007/s002040050444 (Pubitemid 27427514)
24. Bräunlich H., Appenroth D., Fleck C., Protective effects of methimazole against cisplatin-induced nephrotoxicity in rats. Journal of Applied Toxicology 1997 17 1 41 45 2-s2.0-0033988441 10.1002/(SICI)1099-1263(199701)17: 141::AID-JAT388>3.0.CO;2-P (Pubitemid 27091396)
25. Tokunaga J., Kobayashi M., Kitagawa A., Nakamura C., Arimori K., Nakano M., Protective effects of N-benzoyl amino acids on cisplatin nephrotoxicity in rats. Biological and Pharmaceutical Bulletin 1996 19 11 1451 1456 2-s2.0-0029850638 (Pubitemid 26403251)
26. Tokunaga J., Kobayashi M., Nakamura C., Kitagawa A., Arimori K., Nakano M., Protective effect of N-benzoyl- β -alanine against cisplatin nephrotoxicity in rats. Renal Failure 1996 18 2 225 240 2-s2.0-0029921040 (Pubitemid 26138720)
27. Appenroth D., Winnefeld K., Schroter H., Rost M., Beneficial effect of acetylcysteine on cisplatin nephrotoxicity in rats. Journal of Applied Toxicology 1993 13 3 189 192 2-s2.0-0027160113 10.1002/jat.2550130309 (Pubitemid 23151257)
28. Hayashi T., Watanabe Y., Kumano K., Kitayama R., Muratani T., Yasuda T., Saikawa I., Katahira J., Kumada T., Shimizu K., Protective effect of piperacillin against the nephrotoxicity of cisplatin in rats. Antimicrobial Agents and Chemotherapy 1989 33 4 513 518 2-s2.0-0024523702 (Pubitemid 19094283)
29. Rjiba-Touati K., Boussema I. A., Belarbia A., Achour A., Bacha H., Protective effect of recombinant human erythropoietin against cisplatin-induced oxidative stress and nephrotoxicity in rat kidney. International Journal of Toxicology 2011 30 5 510 517 2-s2.0-84857322335 10.1177/1091581810411931
30. Rjiba-Touati K., Ayed-Boussema I., Bouaziz C., Belarbia A., Azzabi A., Achour A., Hassen W., Bacha H., Protective effect of erythropoietin against cisplatin-induced nephrotoxicity in rats: antigenotoxic and antiapoptotic effect. Drug and Chemical Toxicology 2012 35 1 89 95 2-s2.0-80054809746 10.3109/01480545.2011.589440
31. Lee K. W., Jeong J. Y., Lim B. J., Chang Y. K., Lee S. J., Na K. R., Shin Y. T., Choi D. E., Sildenafil attenuates renal injury in an experimental model of rat cisplatin-induced nephrotoxicity. Toxicology 2009 257 3 137 143 2-s2.0-60249083033 10.1016/j.tox.2008.12.017
32. Ulubaş B., Çimen M. Y. B., Apa D. D., Saritaş E., Muşlu N., Çimen Ö. B., The protective effects of acetylsalicylic acid on free radical production in cisplatin induced nephrotoxicity: an experimental rat model. Drug and Chemical Toxicology 2003 26 4 259 270 2-s2.0-0142106817 10.1081/DCT-120024841 (Pubitemid 37267784)
33. Sadzuka Y., Shimizu Y., Takino Y., Hirota S., Protection against cisplatin-induced nephrotoxicity in the rat by inducers and an inhibitor of glutathione S-transferase. Biochemical Pharmacology 1994 48 3 453 459 2-s2.0-0028017751 10.1016/0006-2952(94)90274-7 (Pubitemid 24257007)
34. Nematbakhsh M., Ashrafi F., Safari T., Talebi A., Nasri H., Mortazavi M., Khazaei M., Baradaran-Mahdavi M.-M., Administration of vitamin E and losartan as prophylaxes in cisplatin-induced nephrotoxicity model in rats. Journal of Nephrology 2012 25 3 410 417 2-s2.0-84857603397 10.5301/jn.5000018
35. Weijl N. I., Elsendoorn T. J., Lentjes E. G. W. M., Hopman G. D., Wipkink-Bakker A., Zwinderman A. H., Cleton F. J., Osanto S., Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. European Journal of Cancer 2004 40 11 1713 1723 2-s2.0-3142610921 10.1016/j.ejca.2004.02.029 (Pubitemid 38902907)
36. Argyriou A. A., Chroni E., Koutras A., Iconomou G., Papapetropoulos S., Polychronopoulos P., Kalofonos H. P., A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Supportive Care in Cancer 2006 14 11 1134 1140 2-s2.0-33845454129 10.1007/s00520-006-0072-3 (Pubitemid 44898796)
37. Pace A., Giannarelli D., Galiè E., Savarese A., Carpano S., Della Giulia M., Pozzi A., Silvani A., Gaviani P., Scaioli V., Jandolo B., Bove L., Cognetti F., Vitamin e neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology 2010 74 9 762 766 2-s2.0-77649243226 10.1212/WNL.0b013e3181d5279e
38. Gonçalves A. R. R., Fujihara C. K., Mattar A. L., Malheiros D. M. A. C., Noronha I. D. L., De Nucci G., Zatz R., Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory. American Journal of Physiology 2004 286 5 F945 F954 2-s2.0-1942503350 10.1152/ajprenal.00238.2003 (Pubitemid 38508995)
39. Vaziri N. D., Bai Y., Ni Z., Quiroz Y., Pandian R., Rodriguez-Iturbe B., Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction. Journal of Pharmacology and Experimental Therapeutics 2007 323 1 85 93 2-s2.0-34548813412 10.1124/jpet.107.123638 (Pubitemid 47443257)
40. Ullman J., Eriksson S., Rundgren M., Losartan increases renal blood flow during isoflurane anesthesia in sheep. Acta Anaesthesiologica Scandinavica 2001 45 9 1168 1175 2-s2.0-0034781998 10.1034/j.1399-6576.2001.450919.x (Pubitemid 32996088)
41. Dukacz S. A. W., Kline R. L., Differing effects of enalapril and losartan on renal medullary blood flow and renal interstitial hydrostatic pressure in spontaneously hypertensive rats. Journal of Hypertension 1999 17 9 1345 1352 2-s2.0-0032710863 10.1097/00004872-199917090-00016 (Pubitemid 29509515)
42. Cho J. J., Cadet P., Salamon E., Mantione K. J., Stefano G. B., The nongenomic protective effects of estrogen on the male cardiovascular system: clinical and therapeutic implications in aging men. Medical Science Monitor 2003 9 3 RA63 RA68 2-s2.0-0037355232 (Pubitemid 36389409)
43. Chaudry I. H., Choudhry M. A., 17 β -estradiol: a novel hormone for improving immune and cardiovascular responses following trauma-hemorrhage. Journal of Leukocyte Biology 2008 83 3 518 522 2-s2.0-43349108281 10.1189/jlb.0607369 (Pubitemid 351966860)
44. Dubey R. K., Jackson E. K., Cardiovascular protective effects of 17 β -estradiol metabolites. Journal of Applied Physiology 2001 91 4 1868 1883 2-s2.0-0034807672 (Pubitemid 32900383)
45. Mendelsohn M. E., Protective effects of estrogen on the cardiovascular system. American Journal of Cardiology 2002 89 12, supplement 1 12E 18E 2-s2.0-0036080785 (Pubitemid 34655810)
46. Mendelsohn M. E., Karas R. H., The protective effects of estrogen on the cardiovascular system. New England Journal of Medicine 1999 340 23 1801 1811 2-s2.0-0033542402 10.1056/NEJM199906103402306 (Pubitemid 29266405)
47. Nematbakhsh M., Ghadesi M., Hosseinbalam M., Khazaei M., Gharagozlo M., Dashti G., Rajabi P., Rafieian S., Oestrogen promotes coronary angiogenesis even under normoxic conditions. Basic and Clinical Pharmacology and Toxicology 2008 103 3 273 277 2-s2.0-49749111071 10.1111/j.1742-7843.2008.00286.x
48. Kang D. H., Yu E. S., Yoon K. I., Johnson R., The impact of gender on progression of renal disease: potential role of estrogen-mediated vascular endothelial growth factor regulation and vascular protection. American Journal of Pathology 2004 164 2 679 688 2-s2.0-1542379706 (Pubitemid 38364681)
49. Silbiger S. R., Neugarten J., The role of gender in the progression of renal disease. Advances in Renal Replacement Therapy 2003 10 1 3 14 2-s2.0-0037288810 10.1053/jarr.2003.50001 (Pubitemid 36278325)
50. He Q., Liang C. H., Lippard S. J., Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proceedings of the National Academy of Sciences of the United States of America 2000 97 11 5768 5772 2-s2.0-0034705031 10.1073/pnas.100108697 (Pubitemid 30367473)
51. Beleh M. A., Lin Y. C., Brueggemeier R. W., Estrogen metabolism in microsomal, cell, and tissue preparations of kidney and liver from Syrian hamsters. Journal of Steroid Biochemistry and Molecular Biology 1995 52 5 479 489 2-s2.0-0029020803 10.1016/0960-0760(95)00003-I
52. Nematbakhsh M., Talebi A., Nasri H., Safari T., Dolatkhah S., Ashrafi F., Jazi F. E., Pezeshki Z., Ebrahimian S., Tooyserkani M., Hassan-Ajili S., Some evidence for sex-based differences in cisplatininduced nephrotoxicity in rats. Clinical and Experimental Medical Letters 2012 53 1-2 29 32
53. Haghighi M., Nematbakhsh M., Talebi A., Nasri H., Ashrafi F., Roshanaei K., Eshraghi-Jazi F., Pezeshki Z., Safari T., The role of angiotensin II receptor 1 (AT1) blockade in cisplatin-induced nephrotoxicity in rats: gender-related differences. Renal Failure 2012 34 8 1046 1051 2-s2.0-84865264873 10.3109/0886022X.2012.700886
54. Song J. Y., Kim M. J., Jo H. H., Hwang S. J., Chae B., Chung J. E., Kwon D. J., Lew Y. O., Lim Y. T., Kim J. H., Kim J. H., Kim M. R., Antioxidant effect of estrogen on bovine aortic endothelial cells. Journal of Steroid Biochemistry and Molecular Biology 2009 117 13 74 80 2-s2.0-70249135668 10.1016/j.jsbmb. 2009.07.006
55. Mann V., Huber C., Kogianni G., Collins F., Noble B., The antioxidant effect of estrogen and Selective Estrogen Receptor Modulators in the inhibition of osteocyte apoptosis in vitro. Bone 2007 40 3 674 684 2-s2.0-33846813959 10.1016/j.bone.2006.10.014 (Pubitemid 46201947)
56. Speir E., Yu Z. X., Takeda K., Ferrans V. J., Cannon R. O., Antioxidant effect of estrogen on cytomegalovirus-induced gene expression in coronary artery smooth muscle cells. Circulation 2000 102 24 2990 2996 2-s2.0-0034642319
57. Saad S. Y., Najjar T. A. O., Daba M. H., Al-Rikabi A. C., Inhibition of nitric oxide synthase aggravates cisplatin-induced nephrotoxicity: effect of 2-amino-4-methylpyridine. Chemotherapy 2002 48 6 309 315 2-s2.0-0036971179 10.1159/000069714 (Pubitemid 36407814)
58. Hamilton C. A., Groves S., Carswell H. V. O., Brosnan M. J., Graham D., Dominiczak A. F., Estrogen treatment enhances nitric oxide bioavailability in normotensive but not hypertensive rats. American Journal of Hypertension 2006 19 8 859 866 2-s2.0-33746303621 10.1016/j.amjhyper.2006.01.008 (Pubitemid 44107693)
59. Leung E. L., Fraser M., Fiscus R. R., Tsang B. K., Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance. British Journal of Cancer 2008 98 11 1803 1809 2-s2.0-44349175448 10.1038/sj.bjc.6604375 (Pubitemid 351748840)
60. Nematbakhsh M., Khazaei M., The effect of estrogen on serum nitric oxide concentrations in normotensive and DOCA Salt hypertensive ovariectomized rats. Clinica Chimica Acta 2004 344 1-2 53 57 2-s2.0-2442434731 10.1016/j.cccn.2004. 01.019 (Pubitemid 38626136)
61. Soylemez S., Gurdal H., Sepici A., Akar F., The effect of long-term resveratrol treatment on relaxation to estrogen in aortae from male and female rats: role of nitric oxide and superoxide. Vascular Pharmacology 2008 49 2-3 97 105 2-s2.0-50949093304 10.1016/j.vph.2008.06.006
62. Wink D. A., Cook J. A., Christodoulou D., Krishna M. C., Pacelli R., Kim S., Degraff W., Gamson J., Vodovotz Y., Russo A., Mitchell J. B., Nitric oxide and some nitric oxide donor compounds enhance the cytotoxicity of cisplatin. Nitric Oxide 1997 1 1 88 94 2-s2.0-0031425653 10.1006/niox.1996.0108 (Pubitemid 28078131)
63. Baxi D. B., Singh P. K., Vachhrajani K. D., Ramachandran A. V., Melatonin supplementation in rat ameliorates ovariectomy-induced oxidative stress. Climacteric. In press
64. Srivastava R. C., Farookh A., Ahmad N., Misra M., Hasan S. K., Husain M. M., Evidence for the involvement of nitric oxide in cisplatin-induced toxicity in rats. BioMetals 1996 9 2 139 142 2-s2.0-0029915572 (Pubitemid 26144593)
65. Watanabe K. I., Hess A., Bloch W., Michel O., Expression of inducible nitric oxide synthase (iNOS/NOS II) in the vestibule of guinea pigs after the application of cisplatin. Anti-Cancer Drugs 2000 11 1 29 32 2-s2.0-0034106199 10.1097/00001813-200001000-00005 (Pubitemid 30166701)
66. Watanabe K. I., Hess A., Michel O., Yagi T., Nitric oxide synthase inhibitor reduces the apoptotic change in the cisplatin-treated cochlea of guinea pigs. Anti-Cancer Drugs 2000 11 9 731 735 2-s2.0-0033669739 10.1097/00001813-200010000-00010
67. Santos N. A. G., Catão C. S., Martins N. M., Curti C., Bianchi M. L. P., Santos A. C., Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Archives of Toxicology 2007 81 7 495 504 2-s2.0-34347352096 10.1007/s00204-006-0173-2 (Pubitemid 47012464)
68. Ajith T. A., Usha S., Nivitha V., Ascorbic acid and α -tocopherol protect anticancer drug cisplatin induced nephrotoxicity in mice: a comparative study. Clinica Chimica Acta 2007 375 1-2 82 86 2-s2.0-33750053270 10.1016/j.cca.2006.06.011 (Pubitemid 44584223)
69. Ulas M., Cay M., 17 β -Estradiol and vitamin E modulates oxidative stress-induced kidney toxicity in diabetic ovariectomized rat. Biological Trace Element Research 2011 144 13 821 831 2-s2.0-79953764091 10.1007/s12011-011-9025- x
70. Moorthy K., Sharma D., Basir S. F., Baquer N. Z., Administration of estradiol and progesterone modulate the activities of antioxidant enzyme and aminotransferases in naturally menopausal rats. Experimental Gerontology 2005 40 4 295 302 2-s2.0-16844364267 10.1016/j.exger.2005.01.004 (Pubitemid 40488197)
71. Ulas M., Cay M., Effects of 17 β -estradiol and vitamin E treatments on blood trace element and antioxidant enzyme levels in ovariectomized rats. Biological Trace Element Research 2011 139 3 347 355 2-s2.0-79955953215 10.1007/s12011-010-8669-2
72. Maliakel D. M., Kagiya T. V., Nair C. K. K., Prevention of cisplatin-induced nephrotoxicity by glucosides of ascorbic acid and α -tocopherol. Experimental and Toxicologic Pathology 2008 60 6 521 527 2-s2.0-49949100243 10.1016/j.etp.2008.04.015
73. Goren M. P., Cisplatin nephrotoxicity affects magnesium and calcium metabolism. Medical and Pediatric Oncology 2003 41 3 186 189 2-s2.0-0042844496 10.1002/mpo.10335 (Pubitemid 36910126)
74. Hodgkinson E., Neville-Webbe H. L., Coleman R. E., Magnesium depletion in patients receiving cisplatin-based chemotherapy. Clinical Oncology 2006 18 9 710 718 2-s2.0-33749063400 10.1016/j.clon.2006.06.011 (Pubitemid 44464042)
75. Lajer H., Kristensen M., Hansen H. H., Christensen S., Jonassen T., Daugaard G., Magnesium and potassium homeostasis during cisplatin treatment. Cancer Chemotherapy and Pharmacology 2005 55 3 231 236 2-s2.0-12444330292 10.1007/s00280-004-0899-6 (Pubitemid 40142887)
76. Lajer H., Kristensen M., Hansen H. H., Nielsen S., Frokiær J., Ostergaard L. F., Christensen S., Daugaard G., Jonassen T. E. N., Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemotherapy and Pharmacology 2005 56 5 535 542 2-s2.0-27644583735 10.1007/s00280-005-1010-7 (Pubitemid 41549156)
77. Ariceta G., Rodriguez-Soriano J., Vallo A., Navajas A., Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Medical and Pediatric Oncology 1997 28 1 35 40 2-s2.0-0031021228 10.1002/(SICI)1096- 911X(199701)28:135::AID-MPO7>3.0.CO;2-U (Pubitemid 27023774)
78. Mavichak V., Wong N. L. M., Quamme G. A., Studies on the pathogenesis of cisplatin-induced hypomagnesemia in rats. Kidney International 1985 28 6 914 921 2-s2.0-0022369534 (Pubitemid 16148393)
79. Virág V., May Z., Kocsis I., Blázovics A., Szentmihályi K., Effects of magnesium supplementation on the calcium and magnesium levels, redox homeostasis in normolipidemic and alimentary induced hyperlipidemic rats. Orvosi Hetilap 2011 152 27 1075 1081 2-s2.0-79959203915 10.1556/OH.2011.29152